FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Robinson James A. Jr.
2. Issuer Name and Ticker or Trading Symbol

Urovant Sciences Ltd. [ UROV ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
PEO;CEO/Urovant Sciences, Inc.
(Last)          (First)          (Middle)

C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100
3. Date of Earliest Transaction (MM/DD/YYYY)

3/29/2021
(Street)

IRVINE, CA 92617
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 3/29/2021  D  8385 D (1)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $12.41 3/29/2021  D     50000   (2)3/1/2029 Common Shares 50000 $0.00 0 D  
Stock Option (Right to Buy) $8.78 3/29/2021  D     25000   (2)7/9/2029 Common Shares 25000 $0.00 0 D  
Stock Appreciation Right (Right to Buy) $9.16 3/29/2021  D     845732   (3)3/22/2030 Common Shares 845732 $0.00 0 D  

Explanation of Responses:
(1) Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
(2) Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
(3) Upon consummation of the Merger, each right to receive an appreciation on Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had a strike price per Common Share that is less than $16.25 was canceled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such appreciation right that is equal to the difference between $16.25 and the strike price per Common Share of such appreciation right, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Remarks:
This Form 4 reports securities disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 12, 2020, a copy of which was filed as Exhibit 2.1 to the Form 8-K filed by Urovant Sciences Ltd. (the "Issuer") with the Securities and Exchange Commission on November 13, 2020, and pursuant to which the Issuer became a wholly-owned subsidiary of Sumitovant Biopharma Ltd. (the "Merger"). The Merger was consummated on March 29, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Robinson James A. Jr.
C/O UROVANT SCIENCES, INC.
5281 CALIFORNIA AVENUE, SUITE 100
IRVINE, CA 92617
X
PEO;CEO/Urovant Sciences, Inc.

Signatures
/s/ Bryan Smith, as attorney-in-fact3/31/2021
**Signature of Reporting PersonDate

Urovant Sciences (NASDAQ:UROV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Urovant Sciences Charts.
Urovant Sciences (NASDAQ:UROV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Urovant Sciences Charts.